Literature DB >> 34193994

Controversial Alzheimer's drug approval could affect other diseases.

Asher Mullard.   

Abstract

Entities:  

Keywords:  Alzheimer's disease; Drug discovery; Neurodegeneration; Policy

Mesh：

Substances：

Year:  2021        PMID： 34193994     DOI： 10.1038/d41586-021-01763-9

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

2.  Alzheimer's disease: the controversial approval of Aducanumab.

Authors:  Fabrizio Tagliavini; Pietro Tiraboschi; Antonio Federico
Journal:  Neurol Sci       Date:  2021-07-29       Impact factor: 3.307

Review 3.  Tissue Plasminogen Activator in Central Nervous System Physiology and Pathology: From Synaptic Plasticity to Alzheimer's Disease.

Authors:  Tamara K Stevenson; Shannon J Moore; Geoffrey G Murphy; Daniel A Lawrence
Journal:  Semin Thromb Hemost       Date:  2021-12-23       Impact factor: 6.398

4.  Editorial: Primary Glial and Immune Cell Pathology in Neurodegenerative Diseases.

Authors:  András Lakatos; Gabor Petzold
Journal:  Front Neurol       Date:  2021-10-18       Impact factor: 4.003

5.  A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE).

Authors:  Tereza Cristina Santos Evangelista; Óscar López; Adrián Puerta; Miguel X Fernandes; Sabrina Baptista Ferreira; José M Padrón; José G Fernández-Bolaños; Magne O Sydnes; Emil Lindbäck
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.